To evaluate the current medical insurance coverage of orphan drugs in China, sort out the reimbursement policies and treatment status of rare disease patients, and provide reference for improving the medical insurance treatment of rare disease patients in China.
The number of orphan drugs included in the National Reimbursement Drug List in 2023 was counted. The medical insurance reimbursement policies in 31 provincial capitals (excluding Hong Kong, Macao and Taiwan) were collected, and the status of medical insurance treatment for rare disease patients was evaluated by simulated calculation of Recombinant Human Coagulation Factor VIIa for Injection and Efgartigimod Alfa Injection.
The coverage rates of medical insurance for rare diseases and medical insurance for drugs were 68.42% and 69.88%, respectively. On the whole, the medical insurance reimbursement for rare diseases patients was insufficient, and the proportion of personal self-sufficiency of general outpatients even reached more than 90%.
It is recommended that the we should increase the access of orphan drugs to medical insurance. Each province exploring and implementing the one-way payment policy for orphan drugs. At the municipal level, incorporating more rare diseases into the category of special diseases in outpatient clinics, to improve the level of protection and establish a multi-level security mechanism.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |